Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinica...( Sangamo Announces Completion of Accr...),Health

Sangamo Announces Completion of Accrual and Expansion Plans for SB-509-701

Phase 2 Clinical Trial for Treatment of Moderate to Severe Diabetic

Neuropathy

SAN FRANCISCO, June 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the completion of patient enrollment into its Phase 2 clinical trial (SB-509-701) in subjects with moderate to severe diabetic neuropathy. Additionally, based upon positive initial data, the company plans to expand this study and enroll additional subjects to obtain more information for the design of a potential Phase 3 trial.

"Our initial review of data from SB-509-701, while preliminary, was quite encouraging," stated Dale Ando, M.D., Sangamo's vice president of therapeutic development and chief medical officer. "As such, we plan to double the number of subjects in this study and evaluate an additional treatment schedule. Because of the definitive nature of the endpoint in this trial -- recovery of nerve conduction velocity or NCV -- these additional data may provide important information which could potentially expedite a Phase 3 study."

SB-509-701 is a randomized, single-blind, placebo-controlled, repeat-dosing, multi-center Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic peripheral sensory motor neuropathy (DN). The study is designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetic subjects that have unmeasurable nerve conduction velocity (NCV) in at least one of the nerves in the leg.

In the initial trial, 45 subjects have completed enrollment. Subjects were randomized to one of two groups in a 2:1 ratio. The larger group (approximate
'/>"/>